Antimalarial activity of endoperoxide compound 6-(1,2,6,7-tetraoxaspiro[7.11]nonadec-4-yl)hexan-1-ol

作者：Sato Akira; Hiramoto Akiko; Morita Masayuki; Matsumoto Masahiro; Komich Yuka; Nakase Yukari; Tanigawa Natsuki; Hiraoka Osamu; Hiramoto Kazuyuki; Hayatsu Hikoya; Higaki Kazutaka; Kawai Satoru; Masuyama Araki; Nojima Masatomo; Wataya Yusuke; Kim Hye Sook^*

来源：Parasitology International, 2011, 60(3): 270-273.

DOI：10.1016/j.parint.2011.04.001

• 6-(1,2,6,7-tetraoxaspiro[7.11]nonadec-4-yl) hexan-1-ol (N-251)
• Antimalarial activity
• Endoperoxide compound
• Plasmodium falciparum
• Plasmodium berghei

Plasmodium falciparum, the major causative parasite for the disease, has acquired resistance to most of the antimalarial drugs used today, presenting an immediate need for new antimalarial drugs. Here, we report the in vitro and in vivo antimalarial activities of 6-(1,2,6,7-tetraoxaspiro[7.11]nonadec-4-yl)hexan-1-ol (N-251) against P. falciparum and Plasmodium berghei parasites. The N-251 showed high antimalarial potencies both in the in vitro and the in vivo tests (EC(50) 2.3 X 10(-8) M; ED(50) 15 mg/kg (per oral)). The potencies were similar to that of artemisinin in vitro and greater than artemisinin's activity in vivo (p.o.). In addition, N-251 has little toxicity: a single oral administration at 2000 mg/kg to a rat gave no health problems to it. Administration of N-251 to mice bearing 1% of parasitemia (per oral 68 mg/kg, 3 times a day for 3 consecutive days) resulted in a dramatic decrease in the parasitemia: all the 5 mice given N-251 were cured without any recurrence, with no diarrhea or weight loss occurring in the 60 days of experiment. N-251 deserves more extensive clinical evaluation, desirably including future trials in the human.

• 出版日期2011-9